Phase II study of Rituximab combined with THP-COP as first-line therapy for patients younger than 70 years with diffuse large B cell lymphoma.
Hara T, Tsurumi H, Goto N, Kitagawa J, Kanemura N, Yoshikawa T, Kasahara S, Goto H, Fukuno K, Yamada T, Sawada M, Yasuda I, Katsumura N, Takahashi T, Takami T, Moriwaki H.
Hara T, et al. Among authors: moriwaki h.
J Cancer Res Clin Oncol. 2010 Jan;136(1):65-70. doi: 10.1007/s00432-009-0637-x.
J Cancer Res Clin Oncol. 2010.
PMID: 19590893
Clinical Trial.